Emergent BioSolutions Inc.

Total Valuation

Emergent BioSolutions Inc. carries a market capitalization of 394.71M, placing it among publicly traded companies globally. Its enterprise value stands at 852.58M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Emergent BioSolutions Inc. currently has 51.80M shares outstanding.

Valuation Ratios

Emergent BioSolutions Inc. trades at a trailing price-to-earnings ratio of 21.33. The price-to-sales ratio is 0.68, and the price-to-book ratio stands at -2.87.

Enterprise Valuation

On an enterprise value basis, Emergent BioSolutions Inc. trades at an EV/EBITDA multiple of 5.11 and an EV/FCF ratio of 35.55. The EV/Sales ratio of 1.32 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 11.70 provides insight into valuation relative to core operating earnings.

Financial Position

Emergent BioSolutions Inc. maintains a current ratio of 4.29, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 109.65, indicating elevated leverage, while an interest coverage ratio of 3.00 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Emergent BioSolutions Inc. has paid 12.10M in income taxes, reflecting an effective tax rate of 345.71.

Stock Price Statistics

Emergent BioSolutions Inc.'s stock has gained approximately 10.23055% over the past 52 weeks. The 50-day moving average sits at 8.28, while the 200-day moving average is 9.70.

Income Statement

Over the trailing twelve months, Emergent BioSolutions Inc. generated 645.80M in revenue and converted that into -8.60M in net income, yielding earnings per share of -0.16. EBITDA reached 166.80M, while operating income came in at 72.90M.

Balance Sheet

Emergent BioSolutions Inc. holds 160.30M in cash and equivalents against 573.60M in total debt, resulting in a net debt position of 413.30M. Total book value stands at -152.90M, with working capital of 488.90M providing operational flexibility.

Cash Flow

Emergent BioSolutions Inc. produced 148.00M in operating cash flow over the past twelve months. After subtracting -12.60M in capital expenditures, free cash flow totaled 135.40M - equivalent to 2.56 per share.

Margins

Emergent BioSolutions Inc. operates with a gross margin of 52.04, reflecting its pricing power and cost economics. The operating margin of 11.29 and net profit margin of -1.33 provide insight into operational efficiency.

Dividends & Yields

Scores

Emergent BioSolutions Inc. posts an Altman Z-Score of 1.81, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.